Welcome to the Bioasis Technologies Hub On AGORACOM
Discovery of a Highly Conserved Peptide in the Iron Transporter Melanotransferrin that Traverses an Intact Blood Brain Barrier and Localizes in Neural Cells
A Nanomule Peptide Carrier Delivers siRNA Across the Intact Blood-Brain Barrier to Attenuate Ischemic Stroke
Transcend-trastuzumab BT2111 article (access/subscription required)
biOasis Announces Publication of Scientific Paper – Transcend-Based Anti-Cancer Antibody BT2111
biOasis Announces Publication of Scientific Paper – Transcend-Based Anti-Cancer Antibody BT2111 Crosses the Blood-Brain Barrier and Shows Efficacy in the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brains of Animal Model. Here is the link to the article abstract on NCBI PubMed: http://www.ncbi.nlm.nih.gov/pubmed/27528392
A Holiday Season Note from the CEO 12/26/2015
biOasis had a wonderful year ..... From being awarded a significant research grant, to numerous research collaborations producing key data validation, to new global patents being issued - the highlights of 2015 have put the company in a position of strength as we move into a new realm of exciting possibilities in 2016.
biOasis Technologies Enters into a License Agreement with Astellas Research Institute of America LLC
biOasis Announces the Successful Delivery to the CNS of an Enzyme used to Treat Hunter Syndrome
biOasis Announces the Issuance of a Key US Patent
biOasis Announces the Issuance of a Key US Patent for the Delivery Through the Blood-Brain Barrier of Therapeutic Antibodies – Inclusive of Trastuzumab – to Treat Her2/neu Brain Metastases
BiOasis Fall 2015 Summary Report
Since our last company update in March, biOasis Technologies has been active in scientific development, at international conferences, and with new Technology Access agreements that are pointing towards a prosperous future. Rob Hutchison, CEO of biOasis Technologies, is here to discuss the positive growth of the company in more detail.